{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:34:26Z","timestamp":1783524866524,"version":"3.55.0"},"reference-count":34,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hypereosinophilic syndromes (HESs) are a heterogeneous group of rare disorders characterized by peripheral eosinophilia and eosinophilic end organ complications. Conventional therapies, including glucocorticoids and cytotoxic and immunomodulatory agents, have variable efficacy and significant toxicity. Although the recent development of agents that target eosinophils, including tyrosine kinase inhibitors and monoclonal antibodies, provides the possibility of more effective, less toxic approaches to treatment of HES, there are little available data to guide their use in these conditions. In the following review, the controversies regarding the definition and classification of HES will be discussed, and a pragmatic approach to treatment based on clinically defined HES variants will be presented. An illustrative case will be used to highlight the complexities of treatment selection in HES patients.<\/jats:p>","DOI":"10.1182\/asheducation-2018.1.326","type":"journal-article","created":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T22:13:59Z","timestamp":1555452839000},"page":"326-331","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":55,"title":["Hypereosinophilic syndrome: approach to treatment in the era of precision medicine"],"prefix":"10.1182","volume":"2018","author":[{"given":"Amy","family":"Klion","sequence":"first","affiliation":[{"name":"Human Eosinophil Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"3","key":"2019111600270405800_B1","doi-asserted-by":"crossref","first-page":"668","DOI":"10.7326\/0003-4819-42-3-668","article-title":"Fibroplastic endocarditis with eosinophilia (L\u00f6ffler\u2019s endocarditis parietalis fibroplastica): case report and review of literature","volume":"42","author":"Hoffman","year":"1955","journal-title":"Ann Intern Med"},{"issue":"1","key":"2019111600270405800_B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"2019111600270405800_B3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2019111600270405800_B4","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1182\/blood-2014-11-551614","article-title":"How I treat hypereosinophilic syndromes","volume":"126","author":"Klion","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111600270405800_B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jaci.2010.03.042","article-title":"Refining the definition of hypereosinophilic syndrome","volume":"126","author":"Simon","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"2019111600270405800_B6","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/ajh.24880","article-title":"World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management","volume":"92","author":"Gotlib","year":"2017","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111600270405800_B7","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/all.12843","article-title":"Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome","volume":"71","author":"Khoury","year":"2016","journal-title":"Allergy"},{"issue":"1","key":"2019111600270405800_B8","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaip.2017.06.006","article-title":"Hypereosinophilic syndrome subtype predicts responsiveness to glucocorticoids","volume":"6","author":"Khoury","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2019111600270405800_B9","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.jaip.2018.04.033","article-title":"Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome","volume":"6","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2019111600270405800_B10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.jaci.2013.06.037","article-title":"Marked and persistent eosinophilia in the absence of clinical manifestations","volume":"133","author":"Chen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2019111600270405800_B11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s12032-013-0815-1","article-title":"Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance","volume":"31","author":"Helbig","year":"2014","journal-title":"Med Oncol"},{"issue":"4","key":"2019111600270405800_B12","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/QCO.0b013e3283551dbd","article-title":"Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis","volume":"25","author":"Mejia","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2019111600270405800_B13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jaut.2014.01.018","article-title":"Diagnosis and classification of eosinophilic granulomatosis with polyangiitis (formerly named Churg-Strauss syndrome) [published correction appears in J Autoimmun. 2014;55:94]","volume":"48-49","author":"Mouthon","year":"2014","journal-title":"J Autoimmun"},{"issue":"9","key":"2019111600270405800_B14","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2003-07-2393","article-title":"Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes","volume":"102","author":"Pitini","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111600270405800_B15","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.jaci.2009.09.022","article-title":"Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy","volume":"124","author":"Ogbogu","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2019111600270405800_B16","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/j.seminhematol.2012.01.001","article-title":"Treatment of hypereosinophilic syndromes\u2013the first 100 years","volume":"49","author":"Butterfield","year":"2012","journal-title":"Semin Hematol"},{"issue":"2","key":"2019111600270405800_B17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jaip.2014.09.024","article-title":"Hypereosinophilic disorders","volume":"3","author":"Ogbogu","year":"2015","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"2019111600270405800_B18","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"issue":"10","key":"2019111600270405800_B19","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2019111600270405800_B20","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.leukres.2010.08.004","article-title":"Low-dose Nilotinib can maintain complete molecular remissions in FIP1L1\/PDGFRA-positive hypereosinophilic syndrome","volume":"35","author":"Tabouret","year":"2011","journal-title":"Leuk Res"},{"issue":"2","key":"2019111600270405800_B21","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","article-title":"Therapy of the hypereosinophilic syndrome","volume":"89","author":"Parrillo","year":"1978","journal-title":"Ann Intern Med"},{"issue":"4","key":"2019111600270405800_B22","first-page":"928","article-title":"Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome","volume":"97","author":"Demiroglu","year":"1997","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111600270405800_B23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.leukres.2011.09.026","article-title":"Use of pegylated interferon in hypereosinophilic syndrome","volume":"36","author":"Butterfield","year":"2012","journal-title":"Leuk Res"},{"issue":"10","key":"2019111600270405800_B24","doi-asserted-by":"crossref","first-page":"e0185880","DOI":"10.1371\/journal.pone.0185880","article-title":"Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: a randomised trial","volume":"12","author":"Maritati","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"2019111600270405800_B25","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa070812","article-title":"Treatment of patients with the hypereosinophilic syndrome with mepolizumab","volume":"358","author":"Rothenberg","year":"2008","journal-title":"N Engl J Med"},{"issue":"4","key":"2019111600270405800_B26","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.jaci.2010.06.049","article-title":"Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome","volume":"126","author":"Roufosse","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"2019111600270405800_B27","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jaci.2012.07.055","article-title":"Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes","volume":"131","author":"Roufosse","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"20","key":"2019111600270405800_B28","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"2019111600270405800_B29","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"issue":"2","key":"2019111600270405800_B30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2017.12.622","article-title":"Benralizumab (anti-IL5R\u03b1) depletes gut tissue eosinophilia and improves symptoms in hypereosinophilic syndrome with gastrointestinal involvement","volume":"141","author":"Kuang","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2019111600270405800_B31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcmd.2017.01.008","article-title":"The targeted eosinophil-lowering effects of dexpramipexole in clinical studies","volume":"63","author":"Dworetzky","year":"2017","journal-title":"Blood Cells Mol Dis"},{"issue":"5","key":"2019111600270405800_B32","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2018-02-835330","article-title":"Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes","volume":"132","author":"Panch","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2019111600270405800_B33","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.jid.2016.10.044","article-title":"Treatment of hypereosinophilic syndrome with cutaneous involvement with the jak inhibitors tofacitinib and ruxolitinib","volume":"137","author":"King","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2019111600270405800_B34","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/1078-0432.CCR-08-1302","article-title":"Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"15","author":"Verstovsek","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/326\/1251806\/hem01844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2018\/1\/326\/1251806\/hem01844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,16]],"date-time":"2019-11-16T05:42:44Z","timestamp":1573882964000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2018\/1\/326\/277572\/Hypereosinophilic-syndrome-approach-to-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,11,30]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2018.1.326","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,30]]}}}